A long-acting amylin analog that complements GLP-1 therapy for superior weight loss and metabolic control.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk as part of their next-generation obesity pipeline. Amylin is a pancreatic hormone co-secreted with insulin that plays a critical role in regulating postprandial glucose and satiety. Cagrilintide was engineered with fatty acid modifications to extend its half-life to approximately 7 days, enabling once-weekly dosing. In Phase III trials as part of the CagriSema combination (with semaglutide), it has demonstrated up to 22.7% body weight reduction — substantially exceeding the efficacy of semaglutide alone. This makes it one of the most promising agents in the obesity pharmacotherapy pipeline. Beyond weight loss, it improves glycemic control, reduces postprandial glucose excursions, and has favorable effects on lipid profiles.
“A long-acting amylin analog that complements GLP-1 therapy for superior weight loss and metabolic control.”
Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) — which are calcitonin receptor/RAMP complexes — in the hypothalamus, brainstem (area postrema and nucleus tractus solitarius), and peripheral tissues. Receptor activation reduces food intake through two complementary mechanisms: centrally, it suppresses appetite signals in the hypothalamic arcuate nucleus; peripherally, it slows gastric emptying, reducing the rate of nutrient absorption and prolonging satiety. Cagrilintide’s mechanism is distinct from and complementary to GLP-1 receptor agonists, which act primarily through vagal afferent pathways and cAMP signaling in pancreatic beta cells. The combination of amylin and GLP-1 receptor activation produces synergistic weight loss that exceeds either agent alone, likely because they engage different neural circuits controlling energy homeostasis.
Titrate dose monthly. Often used in combination with semaglutide (CagriSema combination). Requires physician supervision.
When sourcing Cagrilintide for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Multiple randomized controlled trials with high confidence in efficacy and safety data.
Peptides commonly used alongside Cagrilintide for synergistic effects.
Category
Status
Dose
Frequency
Cycle
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
